S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
NASDAQ:APRE

Aprea Therapeutics - APRE Stock Forecast, Price & News

$0.99
+0.04 (+4.21%)
(As of 08/5/2022 08:48 PM ET)
Add
Compare
Today's Range
$0.92
$1.00
50-Day Range
$0.75
$1.25
52-Week Range
$0.62
$5.67
Volume
79,800 shs
Average Volume
590,347 shs
Market Capitalization
$21.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.20

Aprea Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
1.83 Rating Score
Upside/​Downside
223.2% Upside
$3.20 Price Target
Short Interest
Bearish
11.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.12mentions of Aprea Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.12) to ($0.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

811th out of 1,283 stocks

Pharmaceutical Preparations Industry

393rd out of 615 stocks

APRE stock logo

About Aprea Therapeutics (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APRE Stock News Headlines

Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics GAAP EPS of -$0.36 beats by $0.08
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
Why Aprea Therapeutics Is Rising In Pre-market?
See More Headlines
Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APRE Company Calendar

Last Earnings
5/16/2022
Today
8/08/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APRE
Fax
N/A
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.20
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+223.2%
Consensus Rating
Hold
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$-37,130,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.31 per share

Miscellaneous

Free Float
17,206,000
Market Cap
$21.75 million
Optionable
Not Optionable
Beta
0.63

Key Executives

  • Dr. Oren Gilad Ph.D.
    Co-Founder, Chief Exec. Officer, Pres and Director
  • Dr. Kevin D. Smith
    Co-Founder, Director and Advisor
  • Dr. Dansu Li
    Head of Technology
  • Dr. Rifat Pamucku M.D. (Age 64)
    Chief Medical Advisor and Director
  • Mr. Hank Breslin
    Head of Medicinal Chemistry
  • Dr. Michel Afargan
    Head of Pharmacology Devel.
  • Ms. Andrea Epstein
    Controller













APRE Stock - Frequently Asked Questions

Should I buy or sell Aprea Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Aprea Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APRE, but not buy additional shares or sell existing shares.
View analyst ratings for Aprea Therapeutics
or view top-rated stocks.

What is Aprea Therapeutics' stock price forecast for 2022?

6 Wall Street analysts have issued 12 month price objectives for Aprea Therapeutics' shares. Their APRE stock forecasts range from $2.00 to $4.00. On average, they predict Aprea Therapeutics' stock price to reach $3.20 in the next twelve months. This suggests a possible upside of 223.2% from the stock's current price.
View analysts' price targets for Aprea Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Aprea Therapeutics' stock price performed in 2022?

Aprea Therapeutics' stock was trading at $2.87 at the beginning of the year. Since then, APRE shares have decreased by 65.5% and is now trading at $0.99.
View the best growth stocks for 2022 here
.

Are investors shorting Aprea Therapeutics?

Aprea Therapeutics saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 2,080,000 shares, an increase of 154.3% from the June 30th total of 817,900 shares. Based on an average daily trading volume, of 896,800 shares, the days-to-cover ratio is currently 2.3 days. Currently, 11.8% of the shares of the company are sold short.
View Aprea Therapeutics' Short Interest
.

When is Aprea Therapeutics' next earnings date?

Aprea Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Aprea Therapeutics
.

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) issued its earnings results on Monday, May, 16th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.02.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN).

When did Aprea Therapeutics IPO?

(APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets served as the underwriters for the IPO.

What is Aprea Therapeutics' stock symbol?

Aprea Therapeutics trades on the NASDAQ under the ticker symbol "APRE."

How do I buy shares of Aprea Therapeutics?

Shares of APRE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aprea Therapeutics' stock price today?

One share of APRE stock can currently be purchased for approximately $0.99.

How much money does Aprea Therapeutics make?

Aprea Therapeutics (NASDAQ:APRE) has a market capitalization of $21.75 million. The company earns $-37,130,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does Aprea Therapeutics have?

Aprea Therapeutics employs 16 workers across the globe.

How can I contact Aprea Therapeutics?

Aprea Therapeutics' mailing address is 535 BOYLSTON STREET, BOSTON MA, 02116. The official website for Aprea Therapeutics is www.aprea.com. The company can be reached via phone at 609-510-4718 or via email at info@aprea.com.

This page (NASDAQ:APRE) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.